Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Non-Current Assets (2023 - 2025)

Historic Non-Current Assets for Zhengye Biotechnology Holding (ZYBT) over the last 3 years, with Q2 2025 value amounting to $41.9 million.

  • Zhengye Biotechnology Holding's Non-Current Assets changed N/A to $41.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $41.9 million, marking a year-over-year change of. This contributed to the annual value of $43.9 million for FY2024, which is 5.42% down from last year.
  • Latest data reveals that Zhengye Biotechnology Holding reported Non-Current Assets of $41.9 million as of Q2 2025.
  • In the past 5 years, Zhengye Biotechnology Holding's Non-Current Assets registered a high of $43.9 million during Q4 2024, and its lowest value of $41.9 million during Q2 2025.
  • Moreover, its 3-year median value for Non-Current Assets was $43.1 million (2023), whereas its average is $43.0 million.
  • The largest annual percentage gain for Zhengye Biotechnology Holding's Non-Current Assets in the last 5 years was 186.07% (2024), contrasted with its biggest fall of 186.07% (2024).
  • Over the past 3 years, Zhengye Biotechnology Holding's Non-Current Assets (Quarter) stood at $43.1 million in 2023, then rose by 1.86% to $43.9 million in 2024, then dropped by 4.62% to $41.9 million in 2025.
  • Its last three reported values are $41.9 million in Q2 2025, $43.9 million for Q4 2024, and $43.1 million during Q4 2023.